| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return | vs S&P 500 ⓘ |
|---|---|---|---|---|---|---|
|
WST
West Pharmaceutical Services
|
Aug 03, 2026 | BUY |
Strong Buy
+5.3% avg upside
18 analysts
|
$412.00
18.21% Upside
|
+0.2% | · |
|
DXCM
Dexcom
|
Jul 31, 2026 | BUY |
Strong Buy
+20.2% avg upside
32 analysts
|
$88.00
1.27% Upside
|
+4.2% | · |
|
BAX
Baxter International
|
Jul 31, 2026 | HOLD |
Buy
+16.0% avg upside
23 analysts
|
$28.00
1.28% Downside
|
· | · |
|
BSX
Boston Scientific
|
Jul 31, 2026 | BUY |
Strong Buy
+38.7% avg upside
38 analysts
|
$61.00
24.23% Upside
|
+3.6% | · |
|
GKOS
Glaukos
|
Jul 30, 2026 | BUY |
Strong Buy
-3.7% avg upside
21 analysts
|
$188.00
10.34% Upside
|
+1.2% | · |
|
GEHC
GE Healthcare Technologies Inc
|
Jul 29, 2026 | HOLD |
Strong Buy
+17.4% avg upside
22 analysts
|
$75.00
6.75% Upside
|
-1.3% | · |
|
ISRG
Intuitive Surgical
|
Jul 24, 2026 | BUY |
Strong Buy
+29.8% avg upside
36 analysts
|
— | +10.5% | · |
|
MDT
Medtronic
|
Jul 22, 2026 | BUY |
Buy
+12.9% avg upside
38 analysts
|
$110.00
27.52% Upside
|
+4.3% | · |
|
SYK
Stryker
|
Jul 22, 2026 | BUY |
Strong Buy
+9.4% avg upside
37 analysts
|
$385.00
14.52% Upside
|
+8.6% | · |
|
JNJ
Johnson & Johnson
|
Jul 22, 2026 | BUY |
Strong Buy
-6.8% avg upside
39 analysts
|
$298.00
16.92% Upside
|
+0.3% | · |
|
MMED
MiniMed Group, Inc.
|
Jul 17, 2026 | BUY |
Strong Buy
+13.5% avg upside
13 analysts
|
— | +7.2% | · |
|
ABT
Abbott Laboratories
|
Jul 17, 2026 | BUY |
Strong Buy
+8.9% avg upside
36 analysts
|
$112.00
6.11% Upside
|
+4.8% | · |
|
PEN
Penumbra
|
Jul 08, 2026 | HOLD |
Buy
+2.0% avg upside
23 analysts
|
$350.00
7.99% Upside
|
+2.2% | · |
|
COO
Cooper Co
|
Jul 08, 2026 | HOLD |
Buy
+80.3% avg upside
21 analysts
|
$76.00
1.72% Upside
|
+3.9% | · |
|
EW
Edwards Lifesciences
|
Jul 08, 2026 | BUY |
Strong Buy
+12.4% avg upside
34 analysts
|
$110.00
22.81% Upside
|
-4.3% | · |
|
ITGR
Integer Holdings
|
Jul 08, 2026 | HOLD |
Buy
-17.9% avg upside
16 analysts
|
$96.00
23.18% Downside
|
+37.2% | · |
|
HAE
Haemonetics
|
Jul 08, 2026 | HOLD |
Buy
-20.1% avg upside
17 analysts
|
$79.00
7.51% Downside
|
+13.4% | · |
|
PODD
Insulet
|
Jul 08, 2026 | HOLD |
Strong Buy
+49.6% avg upside
32 analysts
|
$172.00
3.20% Upside
|
+5.9% | · |
|
IART
Integra Lifesciences
|
Jul 08, 2026 | HOLD |
Buy
+140.3% avg upside
21 analysts
|
$19.00
6.17% Upside
|
+3.5% | · |
|
ZBH
Zimmer Biomet Holdings
|
Jul 08, 2026 | HOLD |
Buy
+16.6% avg upside
38 analysts
|
$93.00
2.99% Downside
|
+9.4% | · |
|
TNDM
Tandem Diabetes Care
|
Jul 08, 2026 | HOLD |
Buy
+61.0% avg upside
29 analysts
|
$17.00
15.82% Downside
|
+28.4% | · |
|
IRTC
Irhythm Technologies
|
Jul 08, 2026 | BUY |
Strong Buy
+32.7% avg upside
20 analysts
|
$157.00
23.51% Upside
|
+1.4% | · |
|
SGHT
Sight Sciences
|
Jul 08, 2026 | HOLD |
Buy
+41.5% avg upside
13 analysts
|
$6.00
6.30% Upside
|
-0.2% | · |
|
BLCO
Bausch + Lomb Corporation
|
Jul 08, 2026 | BUY |
Buy
+19.3% avg upside
19 analysts
|
$21.00
25.88% Upside
|
-1.0% | · |
|
ESTA
Establishment Labs Holdings
|
Jul 06, 2026 | HOLD |
Strong Buy
-7.6% avg upside
12 analysts
|
$92.00
2.78% Downside
|
+1.1% | · |
|
BDX
Becton Dickinson
|
Jul 06, 2026 | BUY |
Buy
+14.7% avg upside
25 analysts
|
$198.00
16.30% Upside
|
+6.5% | · |
|
LUNG
Pulmonx
|
May 23, 2025 | HOLD |
Buy
+251.7% avg upside
9 analysts
|
$4.15
101.47% Upside
|
-50.2% | · |
|
CH:ALC
Alcon
|
Nov 16, 2022 | HOLD |
Buy
+24.9% avg upside
35 analysts
|
$55.80
2.56% Downside
|
+1.5% | · |
|
RMD
Resmed
|
Jan 27, 2019 | BUY |
Buy
+4.2% avg upside
27 analysts
|
$120.00
46.30% Downside
|
+77.7% | · |
|
PFE
Pfizer
|
Sep 26, 2016 | BUY |
Buy
+32.0% avg upside
45 analysts
|
$40.00
57.51% Upside
|
+9.1% | · |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.